Fixing Healthcare Means Trusting Doctors and Patients — Not Payers
Legacy payers have had decades to readjust their approach. Costs continue to climb, patients still…
Fixing Healthcare Means Trusting Doctors and Patients — Not Payers
Legacy payers have had decades to readjust their approach. Costs continue to climb, patients still face denials, and physicians remain mired in bureaucracy. It’s time to replace a system built on restrictions with one built on trust — trust in clinicians to practice medicine and in patients to make informed choices. The post Fixing Healthcare…
The Digital Imperative: Why the Future of Surgery Will Be Built on Integrated Intelligence, Not More Devices
The future of surgery will be shaped less by what our tools can do than by how well our systems help humans think when it matters most. The question is no longer whether the OR will evolve. It’s who will lead the transition The post The Digital Imperative: Why the Future of Surgery Will Be…
KFF Health Tracking Poll: The Public’s View of Immigration Enforcement Activities in Health Care Settings
Amid reports of Immigration and Customs Enforcement (ICE) at hospitals and President Trump’s reversal of policy protecting “sensitive locations” like hospitals, KFF’s Health Tracking Poll finds that a majority of the public say they are concerned about the Trump administration’s actions in health care settings.
Trump’s One Big Beautiful Bill Act Darkens Outlook for Government-Backed Clinics
Bluestem Health, a clinic that serves low-income and uninsured patients in Lincoln, Nebraska, has lost money for the last two years. And CEO Brad Meyer fears times will soon get worse for the clinic and its 21,000 patients. That’s because Nebraska is set to become the first state to require certain Medicaid enrollees to work…
Readers Sound Off on NIH Staff Cuts, Work Requirements, and More
Letters to the Editor is a periodic feature. We welcome all comments and will publish a selection. We edit for length and clarity and require full names. ‘The Federal Government’s Loss Is the County’s Gain’ I wanted to thank Rachana Pradhan and Katheryn Houghton for their coverage of the loss of staff at the National Institutes of Health…
Kevin Wang, Suki
Suki is one of the original Ambient scribing, now Ambient intelligence, companies. They’re selling both to providers and to other partners using their tech in their tools and services (think telehealth, other EHR providers like Athena, and more). Kevin Wang is the Chief Medical Officer, and he told me about the evolution of ambient documentation,…
What has been the main impact of MFN?
It is not bringing down US prices, but delaying launches in Europe. Reuters reports: Drug launches in EU markets fell by some 35% in the 10 months since Trump’s executive order, compared with the previous 10 months…Delaying launches at lower EU prices could help secure higher U.S. prices for longer. You can read the full…
Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs
March has seen a slew of executive hires, exits and layoffs across the healthcare industry. For instance, Flare Capital Partners, SCAN Group and Advocate Health named new executives. There were also layoffs at organizations including Oracle, Takeda and Blue Shield of California. The post Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs appeared…
Jimini Health Raises $17M to Scale Clinician-Supervised AI for Behavioral Health
Jimini’s $17 million round was from M13, Town Hall Ventures, LionBird, Zetta Venture Partners and OneMind. The post Jimini Health Raises $17M to Scale Clinician-Supervised AI for Behavioral Health appeared first on MedCity News.
Eli Lilly’s Neuro Prospects Expand to Sleep Science With $6.3B Centessa Acquisition
Centessa Pharmaceuticals’ cleminorexton is part of the orexin agonist drug class, which could introduce a new approach to the treatment of narcolepsy and other sleep disorders. Acquiring Centessa brings Eli Lilly into a group of clinical-stage orexin agonist drug developers that includes Takeda Pharmaceutical, Alkermes, and Eisai. The post Eli Lilly’s Neuro Prospects Expand to…
